Personalized care DNAmito offers a clinical-grade decision support system that personalizes cancer treatment planning using genomics, biology, genetics, clinical data and imaging to tailor radiation therapy, presenting a target for OEM partnerships, hospital oncology departments and contract research organizations seeking precision medicine solutions.

Toxicity risk tests MITOTx is positioned as a next-generation saliva-based SNP and mitochondrial DNA test to assess radiation-induced toxicity risk, creating a cross-sell opportunity with radiation oncology centers and imaging departments looking to optimize dosing and reduce adverse events.

Cost and outcomes focus The platform prioritizes toxicity, tumor control, quality of life and cost-effectiveness, aligning with health systems’ value-based care initiatives and payer conversations, suggesting collaboration angles with hospital value improvement programs and reimbursement-focused teams.

Low scale operations With a small team and revenue under one million, DNAmito is a nimble partner for pilot programs, pilots in regional centers, and co-development deals with larger hospitals or CROs seeking innovative genomics-driven radiation planning without large enterprise commitments.

Tech and web presence The use of accessible web technologies and a modern digital footprint indicates readiness for integrated software deployments, data interoperability projects, and potential API-based collaborations with oncology information systems and electronic health records vendors.